'Confused' FDA panel splits on Alexza's inhaled antipsychotic
This article was originally published in Scrip
Executive Summary
In what was often a chaotic meeting on 12 December, the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) voted 9-8, with one abstention, for approval of Alexza Pharmaceuticals inhaled antipsychotic Adasuve (loxapine) to treat agitation associated with schizophrenia or bipolar disorder in adults – although that vote came with some caveats and a lot of confusion.